727
Participants
Start Date
April 6, 2021
Primary Completion Date
August 31, 2026
Study Completion Date
March 5, 2027
IPN10200
"Stage 1: Several different doses will be administrated in a dose-escalation manner.~One single injection will be injected locally into several sites across the glabellar region.~Stage 2: One single injection will be injected locally into several sites across the glabellar, forehead and lateral Canthal regions.~Stage 3: One single injection will be injected locally into several sites across the upper facial area."
IPN10200 Placebo
"Stage 1: One single injection of study intervention will be injected locally into several sites across the glabellar region.~Stage 2: One single injection will be injected locally into several sites across the glabellar, forehead and lateral Canthal regions.~Stage 3: One single injection will be injected locally into several sites across the upper facial area."
Dysport
Single administration of study intervention in stage 1 / step 2 and 3 only
COMPLETED
CRS Clinical Research Services Berlin GMBH, Berlin
RECRUITING
MEDITI - Clinique Del Mar, Antibes
RECRUITING
Aimed S.A.S, Lyon
RECRUITING
Clinique de Chirurgie Esthétique Iéna, Paris
ACTIVE_NOT_RECRUITING
Interdisciplinary Study Association, Berlin
RECRUITING
ROSENPARK RESEARCH GmbH, Darmstadt
RECRUITING
Privatpraxis Dr. Hilton & Partner, Düsseldorf
RECRUITING
Fachbereich Chemie Institut für Biologie und Molekularbiologie Studiengang Kosmetikwissenschaft, Hamburg
RECRUITING
Dermatologische Gemeinschaftspraxis Blankenfelde-Mahlow, Mahlow
Lead Sponsor
Ipsen
INDUSTRY